Das Zentrum
Multiple Sklerose Zentrum Dresden
Patienteninformation
Kontaktinformation
Behandlungsteam
Studienteam
Neuropsychologie
Mobilitätszentrum
Das Mobilitätszentrum
Ganganalyse
Sprunganalyse
DIERS
EMIQ
Forschungsprojekte
Neuroimmunologisches Labor
Das NIL
Neurofilament-Leichtketten Analyse
Autonomes & Neuroendokrinologisches Funktionslabor
Das ANF
Untersuchungsmethoden
MS Living Lab
Management & Science
Team Management & Science
Projekte
eHealth & Analytics
MSDS 3D
MSDS Klinik & Praxis
MS-HRS
MTRS
MS Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
Deutsch
Deutsch
English (UK)
Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis
NIL
Jahr
Publikationsjahr
2023
Autoren
Autorenliste der Publikation
Ziemssen T, Schlegel E, Groth M, Ettle B, Bopp T.
Verlag
Publisher-Information
Vaccines (Basel). 2023 May 13;11(5):978.
Link
Zur Publikation (externer Server)
https://doi.org/10.3390/vaccines11050978
Tags
Forschungsthemen
Multiple Sklerose
Neuroimmunologie
NIL
2023
Serum neurofilament light chain as a sensitive biomarker for neuromonitoring during extracorporeal membrane oxygenation
NIL
Jahr
2024
Raman Spectroscopy of Optically Trapped Living Human T Cell Subsets and Monocytes
NIL
Jahr
2024
COVID-19 and multiple sclerosis: challenges and lessons for patient care
Multiple Sclerosis
Jahr
2024
Correction: Ziemssen et al. Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC). Vaccines 2023, 11, 1374
NIL
Jahr
2024
SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon Gamma
NIL
Jahr
2024
